Search
Rallybio Corp
RLYBAdd to Watchlist
15.815USD
-0.125-0.78%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
82.90MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.78%
5 Days
-0.66%
1 Month
-6.25%
6 Months
+2135.97%
Year to Date
+2205.06%
1 Year
+4688.07%
Key Figures
15.760Open
15.960High
15.17KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.29%Turnover Ratio
15.940Prev. Close
15.700Low
153.25KTurnover
LossP/E Static
1.32P/B
0.00%Div Yield TTM
-13.90%ROA
16.00052wk High
0.64Volume Ratio
-57.77MNet Profit
5.24MShares
-1.3636EPS TTM
-0.92Beta
-14.98%ROE
2.16052wk Low
1.63%Amplitude
100.00%Gross Margin
82.90MMarket Cap
-0.18Reward/Risk
4.39%Risk Rate
TradingKey Stock Score of Rallybio Corp
Currency: USD Updated: 2026-07-01Key Insights
Rallybio Corp's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 141 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rallybio Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rallybio Corp Highlights
StrengthsRisks
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 858.00K.
Undervalued
The company’s latest PE is -11.69, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.48M shares, decreasing 10.59% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 323.47K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.86.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
8.000
Target Price
+6.10%
Upside Space
Rallybio Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Rallybio Corp Info
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Ticker SymbolRLYB
CompanyRallybio Corp
CEOUden (Stephen)
Websitehttps://rallybio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Rallybio Corp (RLYB)?
The current price of Rallybio Corp (RLYB) is 15.94.
What is the symbol of Rallybio Corp?
The ticker symbol of Rallybio Corp is RLYB.
What is the 52-week high of Rallybio Corp?
The 52-week high of Rallybio Corp is 16.00.
What is the 52-week low of Rallybio Corp?
The 52-week low of Rallybio Corp is 2.16.
What is the market capitalization of Rallybio Corp?
The market capitalization of Rallybio Corp is 84.45M.
Is Rallybio Corp (RLYB) currently rated as Buy, Hold, or Sell?
According to analysts, Rallybio Corp (RLYB) has an overall rating of signal_hold, with a price target of 8.00.
What is the Earnings Per Share (EPS TTM) of Rallybio Corp (RLYB)?
The Earnings Per Share (EPS TTM) of Rallybio Corp (RLYB) is -1.59.